Neurology · Pain ManagementRegulatory Approvalregulatorymid-term

Amneal Pharmaceuticals submits ANDA for Milnacipran Hydrochloride

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Amneal Pharmaceuticals5 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/3/2026, 12:34:04 AM

Assessment confidence: 45% · The main uncertainty is whether medium-relevance evidence fully captures sub-indication-specific dynamics.

Executive Thesis

The submission of an ANDA for Milnacipran Hydrochloride by Amneal Pharmaceuticals signifies a potential shift in the competitive landscape of the pain management market. Pharma strategy teams should closely monitor the FDA's review process, as approval could lead to increased competition and impact pricing strategies. Regulatory context from FDA (FDA AP — LEVOMILNACIPRAN HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 8 ranked evidence items (0 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact on market share and pricing strategies for pain management therapies. The strongest clinical anchor is Efficacy of Dexmedetomidine VS Magnesium Sulphate With Bupivacaine in Erector Spinae Block for Thoracotomy Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 6 regulatory and 1 competitive items passed relevance filtering for Amneal Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc (Humanexa Signals) — sub-indication match (pain). This submission could increase competition in the pain management market, particularly against existing branded products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LEVOMILNACIPRAN HYDROCHLORIDE (SUPPL) (FDA). Entity match (milnacipran hydrochloride); Regulatory pathway relevance (nda). The FDA's review and potential approval of this ANDA will be critical, as it may set precedents for future generic entries in the pain management category.

Key Risks

Elevated medium regulatory exposure for Amneal Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, this ANDA could lead to a decrease in market share for existing branded products, affecting revenue streams in the pain management sector.
Portfolio teams should assess the potential impact on market share and pricing strategies for pain management therapies.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any potential approval outcomes for ANDA205081.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
Outcome from FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LEVOMILNACIPRAN HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (milnacipran hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (milnacipran hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (milnacipran hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (milnacipran hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (milnacipran hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source

Efficacy of Dexmedetomidine VS Magnesium Sulphate With Bupivacaine in Erector Spinae Block for Thoracotomy Pain
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Suction Mini-PCNL Versus Standard PCNL for the Management of 2-4cm Kidney Stones
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effect of Foot Massage on Pain and Analgesic Consumption in Total Knee Prosthesis
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study of the Impact of Virtual Reality Medical Device (HypnoVR® Headset) on Anxiety and Pain in Interventional Radiology.
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc
Humanexa Signalsmedium relevance
Sub-indication match (pain)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)

Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Amneal Pharmaceuticals
Milnacipran Hydrochloride

Commercial impact

medium

If approved, this ANDA could lead to a decrease in market share for existing branded products, affecting revenue streams in the pain management sector.

Regulatory impact

medium

The FDA's review and potential approval of this ANDA will be critical, as it may set precedents for future generic entries in the pain management category.

What to watch

Monitor the FDA's review timeline and any potential approval outcomes for ANDA205081.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.